The recent review and consultations held by the Standing National Committee on Medicines (SNCM) have attracted the giants of the pharma industry as they are keen to discourage the addition of their new lucrative pharma products to the NLEM. The list attracts National Pharmaceutical Pricing Authority's (NPPA) attention as it is legally required to regulate the prices of drugs added to the NLEM under the Drug Price Control Order (DPCO). This is a bitter pill for the industry and the private healthcare sector to swallow, as the business model is to make millions with huge profit margins built into the price of new drugs from patients and their families.
You can read up to 3 premium stories before you subscribe to Magzter GOLD
Log in, if you are already a subscriber
Get unlimited access to thousands of curated premium stories, newspapers and 5,000+ magazines
READ THE ENTIRE ISSUE